Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.97

-2.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robohogs who wrote (17127)	6/18/2005 5:25:11 PM
From: Biomaven	Read Replies (1) of 52153

Really an antibiotic like this needs a big pharma behind it. SEPR pretty clearly indicated they are going to be focusing on neuro and pulmonary indications, so they aren't an obvious fit, particularly with L and MDI launch as you mentioned. I suppose FRX is a possibility in the specialty pharma space. KG I guess is a possibility, but certainly not as good as a big pharma. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next